Shire to Add Manufacturing Capacity for Cinryze
Shire requests a technical transfer from Sanquin to widen its manufacturer base for the production of Cinryze.
Shire announced on Aug. 25, 2015 that it has entered into an agreement with its manufacturing partner for Cinryze (C1 esterase inhibitor [human]), Sanquin Blood Supply, to allow Shire to use other manufacturers in addition to Sanquin to produce enough drug to meet increasing demand. Cinryze is indicated for hereditary angioedema (HAE), a rare genetic disease characterized by recurrent sudden attacks of swelling of the skin or the mucous membranes.
“We wanted the freedom to operate and expand in a way that makes strategic sense for our business,” said Flemming Ornskov, MD, CEO of Shire, in a press release. “When Shire acquired ViroPharma in January 2014, we inherited an arrangement under which Sanquin was the exclusive manufacturer for Cinryze. We’re pleased that Sanquin was open to expanding our partnership and agreeing to support us as we increase production options for this important therapy.”
Under the terms of the agreement, Sanquin will receive royalty payments if certain milestones are met, including the successful technical transfer to a second-source manufacturer.
Source: Shire
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
